Clinical practice guidelines for gastric cancer in Korea: An evidence-based approach

Journal of Gastric Cancer

Volumn 14, Issue 2, 2014, Pages 87-104

  Lee, Jun Haeng ^a   Kim, Jae G ^b   Jung, Hye Kyung ^c   Kim, Jung Hoon ^d   Jeong, Woo Kyoung ^a   Jeon, Tae Joo ^e   Kim, Joon Mee ^f   Kim, Young Il ^c   Ryu, Keun Won ^g   Kong, Seong Ho ^h   Kim, Hyoung Il ^e   Jung, Hwoon Yong ⁱ   Kim, Yong Sik ^g   Zang, Dae Young ^j   Cho, Jae Yong ^e   Park, Joon Oh ^g   Lim, Do Hoon ^a   Jung, Eun Sun ^k   Ahn, Hyeong Sik ^g   Kim, Hyun Jung ^g  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Inha University School of Medicine   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Seoul National University Hospital   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Hallym University Medical Center   (South Korea)

^k The Catholic University of Korea   (South Korea)

more..

Author keywords

Guidelines; Multidisciplinary; Stomach neoplasms

Indexed keywords

BEVACIZUMAB; BIOCHEMICAL MARKER; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROPYRIMIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHROMOENDOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC THERAPY; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE;

EID: 84903937482     PISSN: 2093582X     EISSN: 20935641     Source Type: Journal    
DOI: 10.5230/jgc.2014.14.2.87     Document Type: Article

References (144)

1. Cancer statistics [Internet]. Goyang: National Cancer information Center [cited 2014 Feb 5]. Available from: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.
2. Cause of death statistics [Internet]. Daejeon: Korean Statistical Information Service [cited 2014 Feb 5]. Available from: http://kosis.kr/index/index.jsp.
3. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii-x, 1-173.
4. Turk DJ, Kozarek RA, Botoman VA, Patterson DJ, Ball TJ. Disposable endoscopic biopsy forceps: comparison with standard forceps of sample size and adequacy of specimen. J Clin Gastroenterol 1991;13:76-78.
5. Dandalides SM, Carey WD, Petras R, Achkar E. Endoscopic small bowel mucosal biopsy: a controlled trial evaluating forceps size and biopsy location in the diagnosis of normal and abnormal mucosal architecture. Gastrointest Endosc 1989;35:197-200.
6. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
7. Yang R, Vuitch F, Wright K, McCarthy J. Adequacy of disposable biopsy forceps for gastrointestinal endoscopy: a direct comparison with reusable forceps. Gastrointest Endosc 1990;36:379-381.
8. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al; GRADE Working Group. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-1173.
9. Kobayashi S, Kasugai T, Yamazaki H. Endoscopic differentiation of early gastric cancer from benign peptic ulcer. Gastrointest Endosc 1979;25:55-57.
10. Ryu KW, Lee JH, Choi IJ, Bae JM. Preoperative endoscopic clipping: localizing technique of early gastric cancer. J Surg Oncol 2003;82:75-77.
11. Park DJ, Lee HJ, Kim SG, Jung HC, Song IS, Lee KU, et al. Intraoperative gastroscopy for gastric surgery. Surg Endosc 2005;19:1358-1361.
12. Shim CS. Staining in gastrointestinal endoscopy: clinical applications and limitations. Endoscopy 1999;31:487-496.
13. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc 2011;73:1122-1134.
14. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. Endoscopy 2010;42:705-713.
15. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol 1994;162:329-334.
16. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990;65:1255-1260.
17. Gelfand DW. The multiphasic upper gastrointestinal examination. Radiol Clin North Am 1994;32:1067-1081.
18. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology 2007;242:472-482.
19. Kim JH, Eun HW, Hong SS, Auh YH. Early gastric cancer: virtual gastroscopy. Abdom Imaging 2006;31:507-513.
20. Kim HJ, Kim AY, Oh ST, Kim JS, Kim KW, Kim PN, et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 2005;236:879-885.
21. Kumano S, Murakami T, Kim T, Hori M, Iannaccone R, Nakata S, et al. T staging of gastric cancer: role of multi-detector row CT. Radiology 2005;237:961-966.
22. Makino T, Fujiwara Y, Takiguchi S, Tsuboyama T, Kim T, Nushijima Y, et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery 2011;149:672-679.
23. Park SR, Kim MJ, Ryu KW, Lee JH, Lee JS, Nam BH, et al. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg 2010;251:428-435.
24. Yan C, Zhu ZG, Yan M, Zhang H, Pan ZL, Chen J, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol 2009;100:205-214.
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
26. Goshima S, Kanematsu M, Watanabe H, Kondo H, Shiratori Y, Onozuka M, et al. Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. AJR Am J Roentgenol 2010;195:941-946.
27. Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007;97:1493-1498.
28. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39:883-917.
29. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-699.
30. Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med 2005;30:118-119.
31. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253.
32. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295.
33. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-529.
34. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:1582-1588.
35. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008;49:1928-1935.
36. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756.
37. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003;44:1407-1412.
38. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-221.
39. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610.
40. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, et al. The role of 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging 2011;38:64-73.
41. Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. Surgery 1998;123:127-130.
42. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. Am J Surg 2008;196:587-591.
43. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Hutawatari N, et al. Clinical significance of total gastrectomy for proximal gastric cancer. Anticancer Res 2008;28:2875-2883.
44. Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy reconstructed by jejunal pouch interposition for upper third gastric cancer: prospective randomized study. World J Surg 2005;29:1592-1599.
45. The Korean Gastric Cancer Association, ed. Gastric cancer and gastrointestinal disease. Seoul: Ilchokak, 2011.
46. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14:113-123.
47. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462.
48. Nunobe S, Hiki N, Ohyama S, Fukunaga T, Seto Y, Yamaguchi T. Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. Langenbecks Arch Surg 2008;393:157-162.
49. Shchepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. Am J Surg 1998;175:123-126.
50. Maehara Y, Oiwa H, Tomisaki S, Sakaguchi Y, Watanabe A, Anai H, et al. Prognosis and surgical treatment of gastric cancer invading the pancreas. Oncology 2000;59:1-6.
51. Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, et al. Surgical outcomes and survival after extended multiorgan resection for T4 gastric cancer. Am J Surg 2012;203:107-111.
52. Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg 2009;198:25-30.
53. Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol 2009;100:115-120.
54. Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I, et al. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 2005;90:95-100.
55. Oñate-Ocaña LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincón D, Brom-Valladares R, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 2008;98:336-342.
56. Kobayashi A, Nakagohri T, Konishi M, Inoue K, Takahashi S, Itou M, et al. Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg 2004;8:464-470.
57. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg 2006;202:223-230.
58. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002;236:159-165.
59. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol 2009;16:1304-1309.
60. Sano T, Yamamoto S, Sasako M; Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110- MF. Jpn J Clin Oncol 2002;32:363-364.
61. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563.
62. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg 2007;11:1039-1044.
63. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol 2004;94:477-482.
64. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91.
65. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-1153.
66. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799-806.
67. Chareton B, Landen S, Manganas D, Meunier B, Launois B. Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. J Am Coll Surg 1996;183:190-194.
68. Kang KC, Cho GS, Han SU, Kim W, Kim HH, Kim MC, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Comparison of Billroth I and Billroth II reconstructions after laparoscopy-assisted distal gastrectomy: a retrospective analysis of large-scale multicenter results from Korea. Surg Endosc 2011;25:1953-1961.
69. Kojima K, Yamada H, Inokuchi M, Kawano T, Sugihara K. A comparison of Roux-en-Y and Billroth-I reconstruction after laparoscopy-assisted distal gastrectomy. Ann Surg 2008;247:962-967.
70. Kim JP, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol 1995;2:308-313.
71. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg 2007;246:749-753.
72. Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol 2009;16:1896-1902.
73. Youn HG, An JY, Choi MG, Noh JH, Sohn TS, Kim S. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol 2010;17:448-454.
74. Kim MC, Kim W, Kim HH, Ryu SW, Ryu SY, Song KY, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale Korean multicenter study. Ann Surg Oncol 2008;15:2692-2700.
75. Song J, Lee HJ, Cho GS, Han SU, Kim MC, Ryu SW, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010;17:1777-1786.
76. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N; Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007;245:68-72.
77. Huscher CG, Mingoli A, Sgarzini G, Brachini G, Binda B, Di Paola M, et al. Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early and advanced gastric cancer: early and long-term results of a 100-patient series. Am J Surg 2007;194:839-844; discussion 844.
78. Fujiwara M, Kodera Y, Misawa K, Kinoshita M, Kinoshita T, Miura S, et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. J Am Coll Surg 2008;206:138-143.
79. Hwang SH, Park do J, Jee YS, Kim MC, Kim HH, Lee HJ, et al. Actual 3-year survival after laparoscopy-assisted gastrectomy for gastric cancer. Arch Surg 2009;144:559-564; discussion 565.
80. Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg 2010;211:33-40.
81. Pugliese R, Maggioni D, Sansonna F, Costanzi A, Ferrari GC, Di Lernia S, et al. Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. Surg Endosc 2010;24:2594-2602.
82. Jiang X, Hiki N, Nunobe S, Fukunaga T, Kumagai K, Nohara K, et al. Long-term outcome and survival with laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Surg Endosc 2011;25:1182-1186.
83. Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Kim JG, et al. Long-term outcomes and survival after laparoscopy-assisted distal gastrectomy for gastric cancer: three-year survival analysis of a single-center experience in Korea. J Surg Oncol 2011;104:511-515.
84. Pak KH, Hyung WJ, Son T, Obama K, Woo Y, Kim HI, et al. Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surg Endosc 2012;26:130-136.
85. Hur H, Jeon HM, Kim W. Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience. J Surg Oncol 2008;98:515-519.
86. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-420.
87. Sano T. Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. Gan To Kagaku Ryoho 2010;37:582-586.
88. Sasaki T. Discussion for gastric cancer treatment guidelines in Japan. Nihon Rinsho 2003;61:13-18.
89. Kahlke V, Bestmann B, Schmid A, Doniec JM, Küchler T, Kremer B. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg 2004;28:369-375.
90. Sarela AI, Yelluri S; Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 2007;142:143-149; discussion 149.
91. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001;48:225-229.
92. Manner H, Rabenstein T, May A, Pech O, Gossner L, Werk D, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol 2009;104:566-573.
93. Choi KS, Jung HY, Choi KD, Lee GH, Song HJ, Kim do H, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011;73:942-948.
94. Jang JS, Choi SR, Qureshi W, Kim MC, Kim SJ, Jeung JS, et al. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. Scand J Gastroenterol 2009;44:1315-1322.
95. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006;9:88-92.
96. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010;97:868-871.
97. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2009;(4):CD004276.
98. Chung JW, Jung HY, Choi KD, Song HJ, Lee GH, Jang SJ, et al. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol 2011;26:884-887.
99. Kang HJ, Kim DH, Jeon TY, Lee SH, Shin N, Chae SH, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010;72:508-515.
100. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005;23:4490-4498.
101. Song SY, Park S, Kim S, Son HJ, Rhee JC. Characteristics of intramucosal gastric carcinoma with lymph node metastatic disease. Histopathology 2004;44:437-444.
102. Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol 2004;85:181-185; discussion 186.
103. Lee H, Yun WK, Min BH, Lee JH, Rhee PL, Kim KM, et al. A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc 2011;25:1985-1993.
104. Ahn JY, Jung HY, Choi KD, Choi JY, Kim MY, Lee JH, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74:485-493.
105. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, et al; NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw 2010;8:378-409.
106. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113-1119.
107. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242.
108. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064.
109. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-843.
110. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-1737.
111. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
112. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
113. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.
114. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.
115. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
116. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
117. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
118. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
119. Cocconi G, DeLisi V, di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263-1266.
120. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067.
121. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984;2:1372-1381.
122. The Gastrointestinal Tumor study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumor study Group. Cancer 1982;49:1362-1366.
123. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
124. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.
125. Lordick F, Kang YK, Salman P, Oh SC, Bodoky G, Kurteva GP, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. ASCO Meeting Abstracts 2013;31 Suppl:4021.
126. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. ASCO Meeting Abstracts 2013;31 Suppl:LBA4001.
127. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314.
128. Park SH, Lim DH, Park K, Lee S, Oh SY, Kwon H, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive case (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). ASCO Annual Meeting Proceedings 2011;29 Suppl:abstr 4004.
129. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-934.
130. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 2000;26:773-779.
131. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol 2002;80:72-78.
132. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
133. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285.
134. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436.
135. The Study Group for Gastrointestinal Pathology, Korean Society of Pathologists. Guidelines for Pathologic Study of Gastric Cancer. Korean J Pathol 1992;26:154-163.
136. International Agency for Research on Cancer, ed. WHO classification of tumors of the digestive system. 4th ed. Lyon: World Health Organization, 2010.
137. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
138. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HI, et al. A standardized pathology report for gastric cancer. Korean J Pathol 2005;39:106-113.
139. Edge SB; American Joint Committee on Cancer, eds. AJCC Cancer Staging Manual. 7th ed. New York (NY): Springer, 2010.
140. Kim A, Bae JM, Kim SW, Gu MJ, Bae YK. HER2 status in gastric adenocarcinomas assessed by immunohistochemistry, automated silver-enhanced in situ hybridization and fluorescence in situ hybridization. Korean J Pathol 2010;44:493-501.
141. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393.
142. Bilous M, Osamura RY, Rüschoff J, van de Vijver M, Hanna W, Penault-Llorca F, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010;41:304-305; author reply 305-306.
143. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
144. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.